相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients
Oren Pasvolsky et al.
BLOOD CANCER JOURNAL (2023)
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA
Michele Cavo et al.
BLOOD (2022)
Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy
Susan Bal et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma
Ibai Goicoechea et al.
BLOOD (2021)
The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression
Almudena Garcia-Ortiz et al.
CANCERS (2021)
Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma
Gang An et al.
LEUKEMIA (2020)
CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent
Jingzhe Wang et al.
PHARMACOLOGICAL RESEARCH (2020)
Multiple Myeloma, Version 3.2021
Shaji K. Kumar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline
Joseph Mikhael et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The impact of response kinetics for multiple myeloma in the era of novel agents
Yuting Yan et al.
BLOOD ADVANCES (2019)
Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation
Rajshekhar Chakraborty et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Influence of Clonal Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts on Progression and Survival in Multiple Myeloma Patients After Autologous Peripheral Blood Stem Cell Transplantation in Long-term Observation
A. Waszczuk-Gajda et al.
TRANSPLANTATION PROCEEDINGS (2018)
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial
Brian G. M. Durie et al.
LANCET (2017)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial
Philippe Moreau et al.
BLOOD (2016)
Assessment of tumoral plasma cells in apheresis products for autologous stem cell transplantation in multiple myeloma
S. Wuilleme et al.
BONE MARROW TRANSPLANTATION (2016)
Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma
Ravi Vij et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence In Situ Hybridization in Multiple Myeloma
Gang An et al.
CLINICAL CANCER RESEARCH (2015)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value
Gang An et al.
HAEMATOLOGICA (2014)
Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
A. Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma
Prashant Kapoor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders
Fiona M. Ross et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
Abdel Kareem Azab et al.
BLOOD (2009)
Contaminating tumour cells in autologous PBSC grafts do not influence survival or relapse following transplant for multiple myeloma or B-cell non-Hodgkin's lymphoma
J. Ho et al.
BONE MARROW TRANSPLANTATION (2009)
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
JA Child et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: Results of a multicenter randomized controlled trial
AK Stewart et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support
M Boccadoro et al.
BONE MARROW TRANSPLANTATION (2000)
分享论文
